Literature DB >> 2214018

Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.

K A Page1, N R Landau, D R Littman.   

Abstract

We constructed a recombinant human immunodeficiency virus (HIV) vector to facilitate studies of virus infectivity. A drug resistance gene was inserted into a gp160- HIV proviral genome such that it could be packaged into HIV virions. The HIV genome was rendered replication defective by deletion of sequences encoding gp160 and insertion of a gpt gene with a simian virus 40 promoter at the deletion site. Cotransfection of the envelope-deficient genome with a gp160 expression vector resulted in packaging of the defective HIV-gpt genome into infectious virions. The drug resistance gene was transmitted and expressed upon infection of susceptible cells, enabling their selection in mycophenolic acid. This system provides a quantitative measure of HIV infection, since each successful infection event leads to the growth of a drug-resistant colony. The HIV-gpt virus produced was tropic for CD4+ human cells and was blocked by soluble CD4. In the absence of gp160, noninfectious HIV particles were efficiently produced by cells transfected with the HIV-gpt genome. These particles packaged HIV genomic RNA and migrated to the same density as gp160-containing virions in a sucrose gradient. This demonstrates that HIV virion formation is not dependent on the presence of a viral envelope glycoprotein. Expression of a murine leukemia virus amphotropic envelope gene in cells transfected with HIV-gpt resulted in the production of virus capable of infecting both human and murine cells. These results indicate that HIV can incorporate envelope glycoproteins other than gp160 onto particles and that this can lead to altered host range. Like HIV type 1 and vesicular stomatitis virus(HIV) pseudotypes, gp-160+ HIV-gpt did not infect murine NIH 3T3 cells that bear human CD4, confirming that these cells are blocked at an early stage of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2214018      PMCID: PMC248565     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Isolation of noninfectious particles containing Rous sarcoma virus RNA from the medium of Rous sarcoma virus-transformed nonproducer cells.

Authors:  H L Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1967-06       Impact factor: 11.205

4.  Frameshift and intragenic suppressor mutations in a Rous sarcoma provirus suggest src encodes two proteins.

Authors:  G Mardon; H E Varmus
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

5.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

6.  Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene.

Authors:  L L Stuve; S Brown-Shimer; C Pachl; R Najarian; D Dina; R L Burke
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

7.  Naturally occurring murine leukemia viruses in wild mice: characterization of a new "amphotropic" class.

Authors:  J W Hartley; W P Rowe
Journal:  J Virol       Date:  1976-07       Impact factor: 5.103

8.  A murine leukemia virus mutant with a temperature-sensitive defect in membrane glycoprotein synthesis.

Authors:  M Ruta; M J Murray; M C Webb; D Kabat
Journal:  Cell       Date:  1979-01       Impact factor: 41.582

9.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase.

Authors:  R C Mulligan; P Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

View more
  163 in total

1.  HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication.

Authors:  M Srivastava; M Cartas; T A Rizvi; S P Singh; D Serio; V S Kalyanaraman; H B Pollard; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  In vivo assessment of gene delivery to keratinocytes by lentiviral vectors.

Authors:  Ulrich Kuhn; Atsushi Terunuma; Wolfgang Pfutzner; Ruth Ann Foster; Jonathan C Vogel
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration.

Authors:  M L Holmes-Son; S A Chow
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  A noncanonical mu-1A-binding motif in the N terminus of HIV-1 Nef determines its ability to downregulate major histocompatibility complex class I in T lymphocytes.

Authors:  Sayuki Iijima; Young-Jung Lee; Hirotaka Ode; Stefan T Arold; Nobuyuki Kimura; Masaru Yokoyama; Hironori Sato; Yasuhito Tanaka; Klaus Strebel; Hirofumi Akari
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Peter Y Mercredi; Sampson K Kyere; Justin Donlan; Tsutomu Murakami; Michael F Summers; Simon Cocklin; Eric O Freed
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

6.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.

Authors:  F Re; D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

9.  Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.

Authors:  C Aiken; D Trono
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.